Physician profile
Eric D Lonseth
NPI 1073559357
$8,426.58
in general payments reported to CMS, 2019-2025
45 companies · $459 in 2025
The $459 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,184 · 2020: $948 · 2021: $1,762 · 2022: $1,240 · 2023: $1,077 · 2024: $756 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,220.52 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $1,197.24 | 2021-2025 | |
| Pfizer INC. | $726.88 | 2019-2025 | |
| Amgen INC. | $528.07 | 2019-2022 | |
| Vertiflex, INC. | $491.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $453.04 | 2019-2023 | Austedo |
| Biohaven Pharmaceutical Holding Company Ltd. | $401.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $379.53 | 2021 | |
| Forte Bio-Pharma LLC | $319.45 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Novartis Pharmaceuticals Corporation | $287.96 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $187.80 | 2022-2024 | Kloxxado, Ryaltris |
| Sentynl Therapeutics, INC. | $179.28 | 2019-2020 | |
| Bioventus LLC | $166.86 | 2019-2025 | Xcell |
| Stimwave Technologies Incorporated | $166.33 | 2019-2022 | |
| Lilly USA, LLC | $165.99 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lonseth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.